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ABSTRACT An octacosapeptide that we named pro-soma-
tostatin has been isolated from acid extracts of porcine hypo-
thalami and found to have the amino acid sequence Ser-Ala-
Asn-Ser-Asn-Pro-:Ala-Met-Ala-Pro-Arg-Glu-Arg>Lys-Ala-Gly-
Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-C's. This octa-
cosapeptide possesses high somatotropin (growth hormone) and
prolactin release-inhibiting activity in vitro. It also crossreacts
strongly with antisera generated against the somatostatin te-
tradecapeptide. This octacosapeptide is most likely a precursor(pro-hormone) of somatostatin in the hypothalamus. The exis-
tence of still larger molecular size precursors of somatostatin
was also observed.
More than 5 years ago, our laboratory reported larger, more
basic forms of somatostatin in fractions of pig hypothalamic
extract (1, 2). We also recognized two types of immunoreactive
somatostatin in extracts of rat pancreas, stomach, and duo-
denum (3). We suggested, on the basis of physicochemical,
biological, and immunological data, that these substances
represented precursors of somatostatin (1-3). Later, we pos-
tulated that the hypothalamic pro-somatostatin has an extension
at the NH2 terminus containing one or more arginine residues
(4-6). Manual degradation by the Edman-dansyl method
showed the NH2 terminal sequence to be Ser-Ala-Asn-Ser.
However, because of the small amounts available, we were
unable to'complete the entire sequence. Recent developments
in automated amino acid sequence analysis (7), which led to an
increase in sensitivity of several thousandfold, permitted the
successful elucidation of the whole sequence. In this paper we
describe the isolation, biological and immunological charac-
terization, and structural elucidation of putative pro-somato-
statin from porcine hypothalami. The sequence of hypotha-
lamic pro-somatostatin is identical with that of a putative
precursor of somatostatin from pig intestine recently reported
by Pradayrol et al. (8). We conclude that in the hypothalamus,
as in the gut, somatostatin also exists in the form of the pro-
hormone.
MATERIALS AND METHODS
Purification. A total of 630,000 pig hypothalami was dis-
sected, defatted, and extracted as described (9, 10). The major
part of this extract, corresponding to 470,000 hypothalami, was
the same as that used for the isolation of porcine somatostatin
(2) and pro-[Met]enkephalin (11). This extract was purified first
by gel filtration on Sephadex G-25 (9, 10). Fractions containing
immunoreactive somatostatin from the gel filtration were ex-
tracted with the upper phase of 0.1% acetic acid/1-butanol/
pyridine, 11:5:3 (vol/vol), (system I) and 1yophilized. This
material was then further purified by preparative counter-
current distribution (CCD) in the same system by the C-2 model
apparatus (H. 0. Post, New York), followed by chromatography
on carboxymethyl (CM)-cellulose, another CCD in system I for
1800 transfers in the A-4 apparatus, chromatography on SE-
Sephadex, analytical gel filtration on Sephadex G-25, and re-
chromatography on SE-Sephadex. A smaller part of this extract,
corresponding to 160,000 hypothalami, was purified by similar
methods except that free-flow electrophoresis and CCD in 1-
butanol/acetic acid/water, 4:1:5 (vol/vol), were used instead
of other steps. The final purification was done by high-pressure
liquid chromatography (HPLC) (11). In all the steps, the sep-
aration pattern was followed by the Folin-Lowry reaction (12),
by absorbance readings at 278 nm or, for HPLC, at 220 and 280
nm. All the extraction and purification procedures and most
methods used for determination of homogeneity and compo-
sition and for manual Edman-dansyl degradation have been
described (2, 9-11). Automated amino acid sequence analysis
was performed on a spinning cup sequenator designed and built
at California Institute of Technology (7). The sequenator pro-
gram for the Edman degradation was similar to that described
(13). It included a 25-min coupling step with 0.17 M Quadrol
buffer, a single 4-min cleavage step, and automated conversion
of the anilinothiazolinones to phenylthiohydantoin amino acids
by treatment with 25% (vol/vol) aqueous trifluoroacetic acid
for 40 min. The spinning cup and conversion flask were
maintained at 520C. Polybrene (Aldrich, 6 mg) and glycyl-
glycine (100 nmol), dissolved in 0.5 ml of distilled water, were
placed in the sequenator cup and subjected to eight complete
degradation cycles. The pro-somatostatin (2 Ag), dissolved in
0.5 ml of 10% (vol/vol) acetic acid, was then inserted and the
sequencing program was restarted at the coupling stage. On
cycles 6 and 10, the cleavage step was extended to 10 min to
prevent excessive overlap due to incomplete removal of the
prolyl residues (14). Phenylthiohydantoin amino acids were
identified by HPLC on a Dupont Zorbax CN column. Details
of identification of phenylthiohydantoin amino acids by this
method and standard chromatograms have been described
(15).
Bioassays for Pro-Somatostatin Activity. The inhibition of
the release of somatotropin (growth hormone; GH) in vitro
from isolated rat pituitary halves was measured as described
(16). In some experiments, the inhibition of release of GH and
prolactin was measured by using dispersed rat pituitary cells
in monolayer cultures (17). Each sample was assayed in qua-
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druplicate. The concentration of GH and prolactin in the me-
dium was measured by respective radioimmunoassays (RIAs)
(16, 18) with the National Institute of Arthritis, Metabolism and
Digestive Diseases kits.
RIA for Somatostatin. The concentration of porcine pro-
somatostatin activity in various fractions was also followed by
a RIA method for somatostatin (6, 19).
RESULTS
Isolation and Amino Acid Composition. After gel filtration
of 2 M acetic acid extracts from 470,000 pig hypothalami (ly-
ophilized weight, 3.6 kg) on a preparative column of Sephadex
G-25 (2, 9, 10), immunoreactive somatostatin was found in
several fractions. However, about 75% of total RIA activity in
the extract was in fractions 657-856 with RF = 0.7-0.53 (elution
volume/total volume = 0.48-0.63) (see figure 1 of ref. 2). The
total yield of immunoreactive somatostatin from 44 columns
was 14.1 mg in terms of somatostatin tetradecapeptide as as-
sayed by the RIA.
The Sephadex concentrate (382 g) was dissolved in 2800 ml
of the lower phase of system I and extracted five times with the
upper phase. After lyophilization of the combined upper phase,
38 g of extract was obtained, which contained 2.4 mg of im-
munoreactive equivalents of somatostatin or 17% of the total.
The lower phase residue weighed 380 g and contained 11.8 mg
of immunoreactive somatostatin. The extract inhibited GH
release in vitro in doses of 40 ,g/ml and the residue in doses
of 500,Mg/ml.
The upper phase extract was subjected to 250 transfers by
CCD in system I. As reported (2), this procedure completely
separated porcine somatostatin found in fractions 140-180 (K
= 1.7) from pro-somatostatin fractions with a mean K = 0.07
(K is the partition coefficient). These pro-somatostatin fractions
weighed 6.8 g and were equivalent to 900 lug of immunoreac-
tive somatostatin. These fractions, in doses of 8 gtg/ml, also
inhibited GH release from isolated pituitary halves by 50% or
more (Table 1).
Materials with pro-somatostatin activity from CCD I were
purified by ion-exchange chromatography on a CM-cellulose
column. The separation pattern can be seen in Fig. 1. Immu-
noreactive pro-somatostatin activity appeared in fractions
331-348, with a conductivity of 18.0-20.6 mS. These fractions
also inhibited GH release in vitro from pituitary halves in doses
of 1 Mg/ml (Table 1). These fractions were combined, yielding
119 mg. Because only about one-third of immunoreactivity was
recovered, a great loss of pro-somatostatin occurred in this
step.
Table 1. Effect of porcine pro-somatostatin on release ofGH
from rat pituitaries
Dose
Purification dry wt, Medium GH, P vs.
stage /Ag/ml % of control* control
Control 91.7 ± 3.6
CCD I 8 38.5 ± 3.8 0.01
Control 91.6 L 3.4
CCDI 2 47.4 I 12 0.01
Control 111.7 1 12.7
Free-flow electrophoresis 2 52.6 : 6.6 0.01
Control 136.8 I 9.9
CM-cellulose 1 79.8 ± 2.6 0.01
Control 119 ± 7.4
CCD II 0.2 71 + 6.5 0.01














180 200 220 240 260 280 300 320 340 360 380
Fraction
FIG. 1. Chromatography of 6.8 g of pro-somatostatin concentrate
from CCD I on a CM-cellulose column (2.6 X 68 cm) equilibrated with
2mM ammonium acetate buffer (pH 4.5). Gradient 1, to pH 7, 0.1 M
buffer, through a 2000-ml mixing flask, was started at fraction 26;
gradient 2, to pH 7,0.25 M buffer was applied at fraction 197; gradient
3, to pH 7, 0.5M buffer was started at fraction 288. Fraction size was
25 ml. Hatched bar at bottom indicates immunoreactive somato-
statin.
The fractions from CM-cellulose were subjected to 1800
transfers by CCD in system I (Fig. 2). The RIA for somatostatin
showed the presence of immunoreactive material in fractions
220-399 (meanK = 0.12). These fractions weighed 42.8mg and
contained 5.9 ng of pro-somatostatin per Mug of RIA or a total
of 253 ,g. The same fractions also powerfully inhibited GH
release in vitro in doses of 0.2 ,g dry weight/ml (Table 1).
The active fractions were repurified by chromatography and
rechromatography on SE-Sephadex. The separation pattern for
the rechromatography can be seen in Fig. 3. Fractions 139-150,
with a conductivity of 16.8-17.2 mS, contained pro-somato-
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FIG. 2. CCD II of 119 mg of pro-somatostatin from CM-cellulose
in system L. Lower phase was 3 ml; upper phase, 5 ml. The number of
transfers was 1800. Folin-Lowry analyses were done on 50-,4d aliquots
of lower phase (cells 0-399). Hatched bar at bottom indicates im-
munoreactive somatostatin.
SE-Sephadex II 0.2 56.0 A 7.1 <0.01
* (2nd hr/lst hr) X 100. SEM are shown.
Proc. Natl. Acad. Sci. USA 77 (1980)
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FIG. 3. Rechromatography of pro-somatostatin on an SE-
Sephadex column (1.5 X 140 cm), equilibrated with 0.75 M pyridine
acetate buffer (pH 5.3). Fraction size, 10 ml. A linear gradient to 1.8
M buffer (pH 5.3) was started at fraction 28. Hatched bar at bottom
indicates somatostatin immunoreactivity.
The content of pro-somatostatin was 88 ng/Mug dry weight,
equivalent to a total of 211 gg. These fractions, in doses of 0.2
Mg/ml, strongly inhibited GH secretion from rat pituitaries
(Table 1) and also caused a decrease to one-seventh and one-half
the original value, respectively, in GH and prolactin release
from monolayer cultures of rat pituitary cells (Table 2).
The next purification step consisted of rechromatography
on an analytical column of Sephadex G-25 (Fig. 4). Pro-soma-
tostatin emerged in fractions 41-0 with an RF = 0.6. After
Iyophilization, 1.9 mg of material was obtained with a soma-
tostatin immunoreactivity of 95 ng/,ug dry weight. Rechro-
matography on SE-Sephadex did not significantly increase the
specific immunoreactivity of this fraction, which also inhibited
GH and prolactin release from monolayer cultures in doses as
low as 0.05 Mg/ml (Table 2).
This pro-somatostatin (1.1 mg) was combined with another
batch of material (dry weight, 1.5 mg) with equivalent soma-
tostatin immunoreactivity (100 ng/gg) and biological activity,
purified by similar methods from 160,000 hypothalami except
that free-flow electrophoresis (Table 1) and CCD in 1-buta-
nol/acidic acid/water, 4:1:5 (vol/vol), were used instead of
extraction with solvent I. The amino acid composition of both
materials was similar to that of somatostatin except that addi-
tional residues of aspartic acid (two), proline (two), serine (two),
alanine (two), valine (one), lysine (one), and arginine (three)
were also detected. This combined material (3.4 mg dry
weight), which contained 280 Itg of immunoreactive pro-
somatostatin as determined by RIA for somatostatin, was
subjected to HPLC in various systems in batches of 300 ,g in
order to determine the best separation conditions. To minimize
potential adsorption losses on glass, we used polypropylene tubes
Table 2. Effect of porcine pro-somatostatin on release of GH and
prolactin from rat pituitary cells in monolayer cultures
Dose Medium
Purification dry wt, Medium GH,* prolactin,* P vs.
stage Og/ml ng/ml ng/ml control
Control 2560 + 80
1st SE-Sephadex 0.2 230 1 50 <0.01
Control 2560 : 80 2340 : 34
2nd SE-Sephadex 0.2 350 L 30 1800 + 18 <0.01
Control 1288 48 755 + 31
3rd SE-Sephadex 0.05 752 + 125 360 : 56 <0.01
* SEM are shown.
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FIG. 4. Gel filtration of 2.4 mg of pro-somatostatin from SE-
Sephadex on Sephadex G-25 (0.9 X 148 cm). Holdup volume, 28 ml;
solvent, 0.2 M acetic acid; fraction size, 1.0 ml. Folin-Lowry analyses
were done on 50-pAg aliquots. Hatched bar at bottom indicates im-
munoreactive somatostatin.
for collection of fractions in all HPLC steps. Nevertheless, major
losses of pro-somatostatin occurred in HPLC during either
chromatography or flash evaporation and lyophilization, where
contact with glass was unavoidable. After pro-somatostatin
activity was located, the combined active fractions were re-
processed by HPLC. The pattern obtained on HPLC is shown
in Fig. 5. Somatostatin immunoreactivity was found in both
peak I, with a retention time of 40.9 min, and peak II, with a
retention time of 42 min. These peaks were only partially sep-
arated. Because at this stage the dry weight could be unreliable,
the total amount of material was also estimated from amino acid
analysis after hydrolysis. Peak I contained 400 Mg dry
weight-148 ,g of peptide material and 47 Mig of somatostatin
equivalents by RIA. Peak II had 390 MAg dry weight-about 130
Mug of peptide; its immunoreactivity was equivalent to 65Mg of
somatostatin or 166 ng/,Mg dry weight. Portions of both peaks
were used for composition and structural work. The remaining
materials from both peaks were repurified separately by
HPLC.
The HPLC elution profile of 24-,g aliquots of immuno-
reactive material from peak II is illustrated in Fig. 6. The so-
matostatin immunoreactivity emerged in fractions with a re-
tention time of 17-3 min. This fraction contained 16 Mig of
peptide and 7.4 ug of immunoreactive somatostatin. An aliquot
of 1.2 Mg of peptide from this peak was subjected to amino acid
analysis, which gave the following molar ratios: Asp, 3.2; Thr,
1.9; Ser, 2.6; Glu, 1.3; Pro, 1.9; Cys, 2.0; Gly, 1.2; Ala, 3.6; Met,







FIG. 5. Reverse-phase HPLC of pro-somatostatin. Solvent A, 10%1
(vol/vol) CH3CN in 10mM ammonium acetate (pH 4.0). Solvent B,
90% (vol/vol) CH3CN in 10 mM ammonium acetate (pH 4.0) plus 1%
N-ethylmorpholine. The peptide was applied to a g-Bondapak C18
column (0.4 x 30 cm) and eluted isocratically at 0.5 ml/min with 20%
(vol/vol) solvent B for 20 min, then by a linear gradient to 30% (vol/
vol) solvent B at 250C. Hatched bar at bottom indicates somatostatin
immunoreactivity.
Biochemistry: SchaRy et al.
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FIG. 6. Reverse-phase HPLC of pro-somatostatin peak II from
HPLC. The peptide (24 Mg) immunoreactive material was applied to
a ,u-Bondapak C1s column (0.4 X 25 cm) and eluted at 0.5 ml/min with
2-propanol/10 mM ammonium acetate, pH 4.0, by using a linear
gradient of 2-propanol from 20% to 50%o for 50 min' at 250C. Hatched
bar at bottom indicates somatostatin immunoreactive fractions.
Sequential Analyses. Although fractions from peak I of Fig.
5 had higher peptide content, no end group could be detected
by the dansyl procedure. Similarly, automated Edman degra-
dation did not lead to the release of any phenylthiohydantoin
amino acids. Therefore, fractions from Fig. 6 were selected for
amino acid sequence determination. An aliquot of 2 ,ug of
peptide was subjected to manual sequential analyses by the
combined Edman-dansyl procedure for four steps. Another
portion of 2 ,ug was digested with aminopeptidase M, followed
by the dansyl reaction. On the basis of these two experiments,
the NH2-terminal sequence was identified as Ser-Ala-Asn-
Ser.
Another 2-,ug aliquot of the same fractions was subjected to
automated sequence analysis in the Caltech sequenator. This
allowed assignment of 26 amino acid residues as follows:
Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys
Residues were identified by:-, two-dimensional thin-layer
chromatography of dansyl amino acids; -, automated amino
acid sequence determinations (sequenator) and high-sensitivity
HPLC analysis of phenylthiohydantoin amino acids (figures
on identification of phenylthiohydantoin amino acids are
available from the authors); and *, aminopeptidase M digestion
and amino acid analysis. The assignments agreed with the
amino acid composition of the peptide except for the absence
of two residues of Cys. Yields of phenylthiohydantoin-Cys from
the sequenator at the levels of peptide analyzed in this experi-
ment were not sufficient for direct identification. However, the
absence of assignent of any other phenylthiohydantoin amino
acids at cycles 17 and 28 places the Cys residues at these posi-
tions. The proposed primary structure of the pro-somatostatin
is that of the octacosapeptide shown.
Biological and Immunological Characterization. The
extremely small amounts of natural pro-somatostatin octaco-
sapeptide available precluded an extensive evaluation of its
activities in view of the wide variety of endocrine and exocrine
Proc. Natl. Acad. Sci. USA 77 (1980)
effects exerted by somatostatin tetradecapeptide. Natural
pro-somatostatin inhibited GH and prolactin release from
monolayer cultures of rat pituitary cells. Its activity was about
half that of somatostatin on a weight basis. Natural pro-soma-
tostatin was indistinguishable immunologically from synthetic
pro-somatostatin, as indicated by the parallelism of dilution
curves in the RIA system. The slope of the dilution curve for
these pro-somatostatin preparations (b = -1.82) was less steep
than that for synthetic somatostatin (b = -2.51), indicating less
affinity to antiserum A 101 generated against somatostatin te-
tradecapeptide, the recognition sites of which are directed
toward the Asn5 to Serl' portion of the molecule, included in
the ring structure (6).
DISCUSSION
This paper reports the isolation and structure of a putative
pro-somatostatin from porcine hypothalami. This octacosa-
peptide proved to be an NH2-terminally extended form of so-
matostatin.
We detected the presence of very basic, higher molecular
weight, immunoreactive forms of somatostatin in pig hypo-
thalami more than 5 years ago and suggested that they might
represent precursors of somatostatin (1-5). For instance, on the
basis of a large number of CCD distributions, K of pro-soma-
tostatin in solvent I was 0.12 and in solvent II (1-butanol/acetic
acid/water, 4:1:5) it was 0.07, as compared with respective K
values for somatostatin of 1.7 and 0.6. We also reported that the
octacosapeptide with somatostatin activity is also much more
basic than somatostatin; it was eluted from CM-cellulose at 19
mS and from SE-Sephadex at 17 mS, as opposed to somatostatin
for which these values are 11.8 mS and 12 mS, respectively.
Immunological studies (6) using various antisera with different
recognition sites indicated that porcine pro-somatostatin is an
NH2-terminally extended form of somatostatin. However,
because only small amounts of highly purified material were
available, elucidation of the complete structure was delayed.
Subsequently, other laboratories confirmed the presence of
these higher molecular weight forms of somatostatin in rat (20),
pig (21), sheep (22-24), and mouse (25) hypothalamus.
It was also thought that other presumptive precursors of
hypothalamic somatostatin had a large molecular weight (1).
It is probable that part of immunoreactive somatostatin in the
residue remaining in the lower phase of system I represents this
very large molecular weight form of pro-somatostatin (2) be-
cause much of octacosapeptide pro-somatostatin, as well as all
of somatostatin, must have been extracted with the upper
phase.
Large forms of immunoreactive somatostatin were also
previously reported by us in the pancreas, stomach, and duo-
denum of rats (3). Subsequently, other investigators reported
and partially characterized larger immunoreactive forms of
somatostatin in rat (20, 26), dog (27), angler fish (28), and pigeon
(29) pancreas, rat (20), and dog (30) stomach, and human (31)
pancreatic somatostatinoma. Larger forms of immunoreactive
somatostatin were also detected in human serum (32) and rat
plasma (33).
Some of these big forms of somatostatin could be dissociated
by urea into smaller fragments, suggesting that they were not
covalently bound and, therefore, were not authentic higher
molecular weight species (26). Other forms of big immuno-
reactive pro-somatostatin could be dissociated only after
treatment with disulfide bond-reducing agents (27-30),
suggesting that somatostatin may be covalently bound by di-
sulfide bonds to larger polypeptides.
Recently, Pradayrol et al. (8) reported the complete structure
of a putative pro-somatostatin from porcine upper small in-
Proc. Natl. Acad. Sci. USA 77 (1980) 4493
testine. The structure of pro-somatostatin isolated by us from
the hypothalamus is identical to that from the gut (8). Although
the concentration of total immunoreactive somatostatin is
higher in the hypothalamus than in the intestine, the total
content of somatostatin in the intestine is much greater because
of the large size of this organ. From the work of Pradayrol et
al. (8, 34) and our work, it is likely that somatostatin is formed
by cleavage of the Lys-Ala peptide bond in the octacosapeptide
pro-somatostatin. However, a demonstration of the conversion
of the putative pro-somatostatin to somatostatin by the tissues
of origin or appropriate subcellular fractions is necessary to
identify the octacosapeptide as a pro-somatostatin. It is not clear
if the 28-amino-acid octacosapeptide pro-somatostatin is
cleaved post-translationally from a still larger prohormone, but
its existence in both the hypothalamus and the gut suggests that
octacosapeptide could be one of the intermediate physiological
precursors of somatostatin stored in those organs.
The detection of a putative precursor of hypothalamic and
intestinal somatostatin agrees with the previously established
existence of pro-forms of peptide hormones gastrin, insulin,
glucagon, parathyrin, fl-melanotropin, and /3-endorphin (8, 35).
The sequences of regions adjacent to cleavage sites for con-
version of all these peptide pro-hormones invariably contain
two consecutive basic residues (Lys-Lys, Arg-Arg, Lys-Arg, or
Arg-Lys), suggesting that they might be split by trypsin-like
proteolytic enzymes with the resulting formation of the re-
spective hormones. A high frequency of serine and proline
residues was also observed in the precursors. The primary
structure of presumptive pro-somatostatin is in excellent
agreement with these findings because it contains an Arg-Lys
dipeptide in positions immediately preceding the somatostatin
sequence as well as two serine and two proline residues in the
NH2-terminal extension.
The octacosapeptide pro-somatostatin possesses considerable
biological and immunological activity. Its GH and prolactin
release-inhibiting activity in vitro is about 50% of that of so-
matostatin on a weight basis. The immunological activity of
octacosapeptide with antisera directed at the Asn5 to Ser'3
portion of the molecule, including the ring structure, is some-
what smaller than that of somatostatin on a molar basis. We also
observed that with antiserum S 39 (a gift from W. Vale) di-
rected at the NH2 terminus of somatostatin, the octacosapeptide
lacks immunoreactivity. However, because of small amounts
of natural material available, a detailed biological and immu-
nological characterization can be made only with synthetic
octacosapeptide. The availability of the synthetic octacosa-
peptide will permit a complete investigation of its biological
activities-i.e., the inhibition of the release of GH, thyrotropin,
prolactin, insulin, glucagon, gastrin, secretin, cholecystokinin,
and other hormones-as well as its exocrine activity, such as
inhibition of gastric acid, pepsin, and pancreatic bicarbonate,
and other functions.
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